Valuation: GENinCode Plc

Market Cap 6.21M 8.29M 7.22M 6.84M 11.61M 794M 11.66M 81.44M 31.49M 404M 31.16M 30.47M 1.29B P/E 2026 *
-1.18x
P/E 2027 * -
Enterprise Value 5.41M 7.23M 6.29M 5.96M 10.11M 692M 10.16M 70.96M 27.44M 352M 27.15M 26.54M 1.13B EV / Sales 2026 *
1.14x
EV / Sales 2027 * -
Free-Float
59.68%
Yield 2026 *
-
Yield 2027 * -
1 day+3.03%
1 week-10.53%
Current month-19.05%
1 month-3.95%
3 months-8.11%
6 months-20.93%
Current year-64.58%
1 week 0.8
Extreme 0.8
0.97
1 month 0.8
Extreme 0.8
1.25
Current year 0.75
Extreme 0.75
2.5
1 year 0.75
Extreme 0.75
5.5
3 years 0.75
Extreme 0.75
12
5 years 0.75
Extreme 0.75
40
10 years 0.75
Extreme 0.75
48
Manager TitleAgeSince
Chief Operating Officer 51 06/09/2018
Chief Executive Officer 62 06/09/2018
Director of Finance/CFO 57 01/11/2020
Director TitleAgeSince
Chairman 62 06/09/2018
Director/Board Member 51 06/09/2018
Director/Board Member 65 01/05/2020
Date Insider Type Main position Quantity % Market Cap. Importance
6/5/26 Free

Founder

30,428,453 4.0407%
6/5/26 Free

Chairman

1,267,852 0.1684%
6/5/26 Free

Chief Financial Officer

13,523,757 1.7959%
Change 5-day change 1-year change 3-year change Capi.($)
+3.03%-10.53%-79.27%-92.61% 8.35M
+3.26%+13.26%+214.93%+533.30% 23.47B
-0.48%+0.70%-36.53%-21.12% 9.84B
+7.36%+18.70%+512.67%+70.58% 9.47B
+10.19%+28.18%-8.10% - 7.97B
+0.33%+0.48%+98.42%+57.37% 6.56B
+0.22%-0.12%-28.75%-24.49% 5.74B
+1.30%+3.61%-3.12%-16.16% 4.3B
+0.95%-7.49%+54.90%+64.65% 3.74B
+0.78%+0.31%-21.64%-30.67% 2.72B
Average +2.69%+2.59%+70.35%+60.09% 7.38B
Weighted average by Cap. +3.22%+5.68%+136.67%+202.01%

Financials

2026 *2027 *
Net sales 4.73M 6.32M 5.5M 5.21M 8.84M 605M 8.88M 62.03M 23.99M 308M 23.73M 23.21M 984M -
Net income -5.02M -6.7M -5.84M -5.52M -9.38M -642M -9.42M -65.8M -25.44M -326M -25.17M -24.61M -1.04B -
Net Debt -800K -1.07M -930K -881K -1.49M -102M -1.5M -10.49M -4.06M -51.99M -4.01M -3.92M -166M -
Logo GENinCode Plc
GENinCode Plc is a United Kingdom-based predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer. Its testing products include CARDIO inCode Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA Test. Its SITAB is an online Web portal, which provides health care practitioners with a systemized approach to request, record, process and report their clinical and genetic test results. Its CARDIO inCode Score is a genetic test for the evaluation of the coronary genetic load based on a polygenic risk score.
Employees
44
Date Price Change Volume
18/09/26 GBX 0.8500 +3.03% 1,007,575
16/09/26 GBX 0.8250 -2.94% 999,259
15/09/26 GBX 0.8500 0.00% 3,569,065
14/09/26 GBX 0.8500 0.00% 4,093,903
11/09/26 GBX 0.8500 -10.53% 5,699,295
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.008250GBP
Average target price
0.0750GBP
Spread / Average Target
+809.09%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GENI Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!